CRX rs121908004: Vision Health and Cone-Rod Dystrophy
The rs121908004 variant is an ultra-rare single nucleotide variation located in the CRX gene on chromosome 19. It encodes a missense change (often described as Glu80Ala) in the cone-rod homeobox transcription factor, a protein vital for retinal structure and function. Research associates this variant with autosomal dominant cone-rod dystrophy, a rare condition marked by progressive photoreceptor decline.
What each genotype means
Typical retinal health
You carry two reference copies of the CRX gene at this position. This genotype is not associated with the autosomal dominant retinal changes or visual acuity decline seen with the Glu80Ala missense variant.
Found in virtually 100% of individuals across all global populations.
Cone-rod dystrophy risk
You carry one copy of the Glu80Ala (c.239A>C) missense variant in the CRX gene, which is located in the homeodomain critical for photoreceptor maintenance. Published research links this rare heterozygous variant to autosomal dominant cone-rod dystrophy, typically presenting with progressive loss of central visual acuity, color vision deficits, and photophobia.
Extremely rare; absent from standard global population databases such as gnomAD and identified only in rare affected pedigrees.
Genetic Location and Molecular Mechanism
The single nucleotide polymorphism cataloged as rs121908004 is located within the human CRX gene on chromosome 19q13.33. At the protein level, this alteration results in a missense substitution, changing a conserved glutamic acid residue to an alanine residue (Glu80Ala). The CRX gene directs the synthesis of the cone-rod homeobox protein, a homeodomain transcription factor essential for ocular development. Under normal cellular conditions, this protein acts as a master regulator by binding to specific DNA sequences to direct the expression of photoreceptor-specific genes. When a missense mutation occurs in critical functional motifs of CRX, it can impair the homeodomain's capacity to bind DNA or disrupt regulatory partnerships with other retinal transcription factors, such as NRL and NR2E3, compromising the long-term biological integrity of retinal photoreceptors.
Function of the CRX Gene in Retinal Biology
The retina relies on two primary classes of specialized sensory cells to capture light and initiate vision: rod cells and cone cells. Cones are concentrated in the macula and are responsible for daytime visual acuity, central vision, and color perception, while rods dominate the peripheral retina and mediate vision in low-light environments. The CRX transcription factor is expressed prominently in both developing and mature photoreceptors, orchestrating gene programs that sustain outer segment discs, phototransduction cascades, and synaptic connectivity. Although cells carrying heterozygous CRX alterations may successfully complete initial differentiation during embryogenesis, functional deficiency impairs long-term structural maintenance. Over time, the inability to replace vital visual pigments and structural scaffolding leads to cumulative photoreceptor dysfunction and cellular loss.
Clinical Research and Phenotypic Associations
Mutations within CRX are linked in scientific literature to inherited retinal dystrophies, most notably autosomal dominant cone-rod dystrophy 2 (CORD2), and occasionally Leber congenital amaurosis or retinitis pigmentosa. In cone-rod dystrophy, initial visual symptoms typically stem from primary cone deterioration, manifesting as reduced central visual acuity, photophobia (light sensitivity), and impaired color discrimination. As the pathology progresses, adjacent rod cells degenerate, leading to nyctalopia (night blindness) and constricted visual fields. Autosomal dominant transmission means that a single altered allele can be sufficient to precipitate disease features. However, clinical evidence for rs121908004 specifically is characterized as limited due to its ultra-rare frequency, with reports confined to isolated families or small clinical cohorts, demonstrating variable expressivity across affected individuals.
Population Frequency and Data Limitations
Epidemiological sequencing repositories, including large-scale reference datasets like the Genome Aggregation Database (gnomAD), indicate that rs121908004 is an ultra-rare private variant. It is effectively absent from broad, asymptomatic population screening cohorts across all major global ancestries. General cone-rod dystrophies affect an estimated 1 in 30,000 to 40,000 individuals worldwide, with CRX mutations accounting for a fraction of autosomal dominant cases. Because rs121908004 is documented primarily in targeted cohorts evaluated for clinical visual loss, general population-level penetrance calculations remain imprecise. Direct-to-consumer genetic testing platforms infrequently assess this locus with clinical-grade analytical validity, and observed results in general screening tests should be interpreted cautiously within an appropriate clinical framework.
Interpreting Results and Practical Next Steps
A genetic finding involving rs121908004 is informational and does not constitute a standalone medical diagnosis. Visual acuity decline and retinal degeneration require clinical evaluation by an ophthalmologist or a retinal specialist through specialized testing, such as electroretinography (ERG), optical coherence tomography (OCT), and detailed visual field testing. If consumer sequencing or ancestry data suggests the presence of this variant, it is essential to seek confirmation via a CLIA-certified and CAP-accredited diagnostic laboratory. A certified genetic counselor can help interpret familial risk, explain dominant inheritance patterns, and explore whether an individual or family qualifies for emerging clinical registries or gene-specific research trials for inherited retinal dystrophies.
How common is this variant?
The rs121908004 variant is an ultra-rare private allele that is virtually absent from general population databases such as gnomAD. Overall, cone-rod dystrophy affects approximately 1 in 30,000 to 40,000 individuals across global ancestries.
Frequently asked questions
What is the CRX gene and how does it relate to vision?
The CRX gene provides instructions for creating a specialized homeodomain protein that acts as a transcription factor in the retina. It controls the activation of genes required for building and maintaining photoreceptor cells (rods and cones), which are essential for color vision, fine detail, and night vision.
What is cone-rod dystrophy?
Cone-rod dystrophy is an inherited retinal condition characterized by progressive loss of the light-sensitive cells in the eye. Symptoms usually begin with decreased visual acuity, abnormal color perception, and sensitivity to light, followed later by loss of night vision and peripheral field loss.
Does having the rs121908004 variant guarantee vision loss?
While CRX-related cone-rod dystrophy typically follows an autosomal dominant pattern where one copy is associated with disease, specific variants can exhibit variable expressivity. This means that symptom onset, severity, and rate of progression can differ substantially among individuals, even within the same biological family.
Can consumer DNA tests accurately report rs121908004?
Direct-to-consumer genotyping arrays often have higher error rates for ultra-rare variants like rs121908004 compared to common SNPs. Any unexpected finding on a recreational test should be verified using a clinical-grade diagnostic sequencing assay ordered by a medical professional.
Are treatments available for CRX-related retinal disorders?
Currently, standard clinical care focuses on supportive strategies such as low-vision aids, tinted lenses for photophobia, and routine monitoring by an ophthalmologist. However, researchers are actively studying translational approaches, including gene augmentation and transcriptional therapies, in clinical and preclinical trials.
Sources & further reading
Educational information only, last refreshed 9/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908004?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CRX
Pathogenic homeodomain mutation associated with autosomal dominant cone-rod dystrophy and Leber congenital amaurosis.
A dominant missense variant in the CRX homeobox transcription factor causing Leber congenital amaurosis and cone-rod dystrophy.
A missense variant in the CRX homeodomain disrupting retinal photoreceptor cell differentiation and survival.
This variant in the cone-rod homeobox transcription factor gene causes autosomal dominant cone-rod dystrophy and Leber congenital amaurosis.
Pathogenic missense variant in the CRX homeodomain associated with autosomal dominant cone-rod dystrophy and severe visual impairment.
This pathogenic variant in the CRX gene is linked to Retinitis pigmentosa, affecting retinal photoreceptor development.